Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Detection of pancreatic cancer using antibody microarray-based serum protein profiling

  • Johan Ingvarsson
  • Christer Wingren
  • Anders Carlsson
  • Peter Ellmark
  • Britta Wahren
  • Gunilla Engström
  • Ulrika Harmenberg
  • Morten Krogh
  • Carsten Peterson
  • Carl Borrebaeck
Publishing year: 2008
Language: English
Pages: 2211-2219
Publication/Series: Proteomics
Volume: 8
Issue: 11
Document type: Journal article
Publisher: John Wiley & Sons

Abstract english

The driving force behind oncoproteomics is to identify protein signatures that are associated with a particular malignancy. Here, we have used a recombinant scFv antibody microarray in an attempt to classify sera derived from pancreatic adenocarcinoma patients versus healthy subjects. Based on analysis of nonfractionated, directly labeled, whole human serum proteomes we have identified a protein signature based on 19 nonredundant analytes, that discriminates between cancer patients and healthy subjects. Furthermore, a potential protein signature, consisting of 21 protein analytes, could be defined that was shown to be associated with cancer patients having a life expectancy of <12 months. Taken together, the data suggest that antibody microarray analysis of complex proteomes will be a useful tool to define disease associated protein signatures.


  • Immunology in the medical area
  • Biophysics


  • CREATE Health
  • ISSN: 1615-9861
Carl Borrebaeck
E-mail: carl [dot] borrebaeck [at] immun [dot] lth [dot] se


Department of Immunotechnology




Create Health

+46 46 222 96 13